Does Medicare Cover Weight Loss Drugs Now? The $50 GLP-1 Bridge Program, Explained

On July 1, Medicare started covering GLP-1 weight loss medications for a flat $50 a month. If you're 65 or older and have spent the past few years watching these medications from a distance because of the price, that headline probably stopped you mid-scroll. A medication that used to run more than $1,000 a month out of pocket, now $50.

Then you call your plan, or your pharmacy, and the story gets complicated. Which drugs count? Why does the pharmacist need a prior authorization from a system she's never used before? Why does your neighbor's plan quote a different number than yours?

We read the program rules and the reporting behind them so you don't have to. This is what the Medicare GLP-1 Bridge Program actually covers, who qualifies, and the fine print most of the headlines skipped.

What the Medicare GLP-1 Bridge Program Is

The Bridge Program is a federal demonstration project run by CMS, the agency that manages Medicare. Starting July 1, 2026, eligible Medicare Part D beneficiaries can get certain GLP-1 medications for a flat $50 monthly copay. The program is scheduled to run through December 31, 2027.

One detail worth understanding up front: the program operates outside the normal Part D benefit. A central CMS system handles the approvals, processes the claims, and pays pharmacies directly. That's why your pharmacist may be working through paperwork that looks nothing like a regular prescription claim, and why the approval step can take longer than you'd expect for a medication your doctor already prescribed.

Who Qualifies

Eligibility comes down to four requirements:

• Enrollment in Medicare Part D
• A BMI of 27 or higher
• A qualifying health condition, such as heart disease or prediabetes
• Meeting CMS clinical criteria, confirmed through the prior authorization process

If that BMI threshold sounds familiar, it should. It mirrors the standard prescribing criteria for GLP-1 medications generally: a BMI of 27 or higher with a weight-related condition. The qualifying condition piece matters just as much as the number on the scale. A history of cardiac issues, for example, is exactly the kind of thing that should be evaluated properly before starting any weight loss medication, which is part of why we treat heart health as its own conversation rather than a checkbox.

Prediabetes is the other common qualifier, and it's worth pausing on. If your fasting glucose or HbA1c already sits in prediabetic territory, weight is probably not your only metabolic issue. That's a lab conversation, not just a coverage conversation.

Which Medications Are Covered (and Which Are Not)

The covered list is specific. According to CMS, the program includes all formulations of Wegovy, all formulations of Foundayo, and only the KwikPen formulation of Zepbound.

Notice what's missing. Compounded semaglutide is not included. Other formulations and other GLP-1 products are not included. If you're currently on a compounded protocol, or a formulation that didn't make the list, the Bridge Program doesn't apply to your prescription as written. Your prescriber would need to switch you to a covered product, and whether that switch makes clinical sense depends on your history and your labs, not just on the copay. If you want the background on how these medications differ, our semaglutide vs tirzepatide comparison covers it in plain language.

The Fine Print the Headlines Skipped

Four things in the program rules deserve more attention than they've gotten.

The $50 doesn't count toward your other Medicare costs. The Medicare Rights Center flagged this in June: because the program runs outside the standard Part D benefit, the $50 monthly copay does not count toward your Part D deductible or the $2,100 annual out-of-pocket cap. You could pay $600 a year for your GLP-1 and still be at zero on both.

It has an end date. December 31, 2027. What happens after that hasn't been decided. If the program isn't extended, patients who started a medication under the $50 copay could face a very different price 18 months from now. Nobody should start a long-term medication with only a short-term plan for affording it.

Prior authorization is required, through a brand-new system. Approvals run through a central CMS system rather than your plan's usual process. New systems have growing pains. Expect delays, and expect your pharmacy to be learning the process at the same time you are.

The formulation restrictions are strict. Zepbound is only covered in its KwikPen form. If your prescription is written for a different presentation of the same drug, it falls outside the program until it's rewritten.

The Pricing Condition Nobody Announced

The day before the program launched, STAT News published reporting on how the underlying deal was structured, and it explains a lot of the confusion patients are running into.

The 2025 pricing agreement between the federal government and the two major GLP-1 manufacturers, Eli Lilly and Novo Nordisk, carried a condition that was never publicized: private Medicare insurers had to agree to cover GLP-1s broadly at the $50 copay in exchange for receiving the discounted price. In practice, the drugmakers largely gained sales volume, and the broad list-price cuts most patients expected never really arrived.

So if you're under 65 and have been waiting for GLP-1 prices to drop at the pharmacy counter, this is why you haven't seen it. The savings were routed through Medicare plan copays instead of through the list price. And if you're on Medicare and your plan's answers about coverage sound oddly hedged, the hedging has a source: plans absorbed an obligation they didn't choose publicly, and each one implements it differently. We covered the broader pricing mess, including brand list prices and savings-card exclusions for government plans, in our tirzepatide cost breakdown.

The Copay Covers the Drug, Not the Care Around It

Say the prior authorization goes through and your pharmacy hands you a covered GLP-1 for $50. That's genuinely good news. What you're holding is still just the medication, though, with nobody assigned to watch what it does next.

What the Bridge Program does not include: baseline bloodwork to find out why the weight came on in the first place. Thyroid, insulin, and hormone testing to catch the drivers a GLP-1 won't touch. Body composition tracking to make sure the weight coming off is fat and not muscle. Dose titration guided by an actual clinician watching your response. Someone to call when the side effects show up in week three.

That last gap matters more for older adults, not less. Muscle loss during rapid weight loss is a real risk at any age, and after 65 it's the difference between losing weight and losing strength, balance, and independence. It's the reason muscle preservation is built into every weight loss protocol our providers run, with protein targets, strength training guidance, and an InBody 770 scan at every visit so fat mass and muscle mass are tracked separately.

Collin Dees, MPAS, PA-C, and Sophia Viner, DNP, ANP-BC, who lead weight loss care at Med Matrix, build every protocol from an 80+ biomarker lab panel before any prescription gets written. In over 3,000 patients, we've seen the same pattern again and again: stubborn weight with a thyroid problem underneath it, or insulin resistance, or a hormone imbalance that no GLP-1 was ever going to fix on its own. A $50 copay doesn't find any of that. Labs do.

If You're Medicare-Eligible, Do This Before You Fill

A short checklist that will save you phone calls later:

• Confirm you're enrolled in Part D, not just Medicare generally
• Ask your plan about "the Medicare GLP-1 Bridge Program" by name
• Confirm the exact medication and formulation your prescriber wrote is on the covered list
• Get the copay in writing before your first fill
• Remember the $50 won't count toward your deductible or out-of-pocket cap, so budget it as a separate expense
• Get real bloodwork before you start, whoever ends up paying for the medication

And an honest note: if the program fits you, your plan cooperates, and your prescriber is monitoring you properly, use it. Cheaper access to a legitimate, FDA-approved medication is a good thing. What we care about is whether anyone is actually watching what the drug is doing to your body, whoever ends up paying for it.

How Med Matrix Approaches Weight Loss, Whoever Pays for the Medication

Med Matrix is a cash-pay clinic. We don't bill Medicare or private insurance, which means no formulary lists, no prior authorization queues, and no surprise at the counter. It also means you should know exactly what our weight loss program involves before you decide whether it's right for you.

It starts with a free discovery call with a patient coordinator, so we understand what you're dealing with before anything gets scheduled. Then comes the testing: the 80+ biomarker panel, a full body composition scan, and detailed health questionnaires. Our medical team reviews all of it together, cross-referencing your symptoms against your lab patterns, before you sit down for a full hour with your provider to go through every result and build the plan. From there you get ongoing support, with dose adjustments, repeat scans, and direct access to your care team as your body responds.

New-patient onboarding runs approximately $1,200 to $1,500 all-in, follow-up visits are $275, and new patients receive a $100 voucher toward their first visit. HSA and FSA funds work here, and financing options are available. If the medication route turns out to be wrong for you, the labs will show that too. Some patients end up on our semaglutide program, and some discover through functional medicine testing that their weight problem was a thyroid problem wearing a disguise.

Frequently Asked Questions

Does Medicare cover weight loss drugs like Wegovy in 2026?

Yes, through the Medicare GLP-1 Bridge Program that launched July 1, 2026. Eligible Part D beneficiaries with a BMI of 27 or higher and a qualifying condition, such as heart disease or prediabetes, can get covered GLP-1 medications for a flat $50 monthly copay. The covered list includes all formulations of Wegovy and Foundayo and the KwikPen formulation of Zepbound. Prior authorization is required.

Does the $50 copay count toward my Part D deductible or out-of-pocket cap?

No. Because the Bridge Program operates outside the standard Part D benefit, the $50 monthly copay does not count toward your Part D deductible or the $2,100 annual out-of-pocket cap. Budget for it as a separate, standalone cost.

Is compounded semaglutide covered by the Bridge Program?

No. The program covers a specific list of brand-name products, and compounded semaglutide is not on it. Patients on compounded protocols would need a prescriber to switch them to a covered formulation, and that decision should be based on labs and clinical history, not on the copay alone.

What happens when the Bridge Program ends in December 2027?

Nobody knows yet. The program is a demonstration project scheduled to run through December 31, 2027, and no decision about an extension has been announced. Anyone starting a GLP-1 under the $50 copay should have a conversation with their prescriber about the long-term plan, since these medications work best as part of sustained treatment rather than a short stint.

Does Med Matrix bill Medicare?

No. We're a cash-pay clinic, so our pricing is the same regardless of insurance status: approximately $1,200 to $1,500 for full onboarding with labs, body composition scan, and a one-hour provider consultation, then $275 follow-ups. We accept HSA, FSA, and CareCredit. What you're paying for is the clinical side that a pharmacy copay never includes: the testing, the monitoring, and a provider who actually watches your results.

Whether your medication comes through Medicare, private insurance, or a cash-pay program, you deserve bloodwork before your first dose and a care team watching everything after it. Start Feeling Like Yourself Again with a free discovery call and your $100 new-patient voucher.